JPRN-jRCT2041180037已完成2 期
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial - RECIPE Trial
Iijima Masahiro0 个研究点目标入组 25 人开始时间: 2019年1月31日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with definite CIDP diagnosed according to the modified diagnostic criteria of European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) (2010) by the time of enrollment in the study
- •2.Patients meeting one of the following conditions:
- •1)Patients with positive serum IgG4 autoantibody (CNTN-1 or NF-155) confirmed by the time of enrollment in the study
- •2)Patients with negative serum IgG4 autoantibody (CNTN-1 and NF-155) confirmed by the time of enrollment in the study
- •3.Patients with refractory CIDP not responding adequately to treatment with corticosteroids for 12 weeks, and intravenous immunoglobulin therapy (IVIg) for 8 weeks by the time of enrollment in the study, or those who are unable to administer or continue corticosteroids and IVIg
- •4.Patients with total adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale scores of 2 to 8 at both preliminary enrollment and enrollment, and with the total score at enrollment equal to or worse than that at preliminary enrollment
- •5.Patients aged 12 years or older at informed consent
- •6.Patients who give their voluntary written consent after having received adequate information on this study (legally acceptable representatives should also give consent for underage patients, and informed assent should be obtained from children aged 12 to 15)
排除标准
- •1.Patients with disease meeting one of the following exclusion criteria defined in the modified EFNS/PNS diagnostic criteria (2010).
- •1)Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy Hereditary demyelinating neuropathy
- •2)Prominent sphincter disturbance
- •3)Diagnosis of multifocal motor neuropathy
- •4)IgM monoclonal gammopathy with high antibody titers to myelin-associated glycoprotein
- •5)Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy
- •PNS lymphoma and amyloidosis may occasionally have demyelinating features
- •2.Patients who have started or have increased the dose of corticosteroids for CIDP within 12 weeks prior to the enrollment
- •3.Patients who have started or have increased the dose of IVIg within 8 weeks prior to the enrollment
- •4.Patients who have undergone plasmapheresis within 8 weeks prior to the enrollment or patients with refractory disease not responding adequately to 8 weeks of plasmapheresis (plasma exchange or double-filtration plasmapheresis)
- •5. Patients who have started or have increased the dose of an immunosuppressant (azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, interferon alpha, interferon beta, etanercept, methotrexate, mitoxantrone, alemtuzumab, cladribine, tacrolimus, fingolimod) within 12 weeks prior to the enrollment
- •6.Patients who have undergone hematopoietic stem cell transplant prior to the enrollment
- •7.Patients who have used rituximab (genetical recombination) prior to the enrollment
- •8.Patients who have participated in another clinical study within 3 months prior to the enrollment (enrollment is allowed for those participating in a clinical study in the range of Indications or Dosage and Administration in Japan) or patients who are participating in another study
- •9. Patients with poorly controlled diabetes (HbA1c of 7 % or higher)
- •10.Patients who have or are suspected to have active infection (infection requiring treatment with systemic antimicrobial, antifungal, or antiviral agents) at the time of the enrollment
- •11.Patients tested positive for HBs antigen, HBs antibody, HBc antibody, and/or HCV antibody (patients with positive hepatitis B surface antibody or core antibody can be enrolled when a hepatitis B virus-DNA test is negative [below the limit of detection], and hepatitis B virus-DNA and aspartate/alanine transaminase levels are monitored at fixed intervals), or patients with positive HIV antibody or HTLV-1 antibody at the time of the enrollment
- •12.Patients with leukopenia (less than 2,000 /mm3), neutropenia (less than 1,000 /mm3), or lymphopenia (less than 500 /mm3) at the time of the enrollment
- •13.Patients with history of serious hypersensitivity or anaphylactic reaction to one of the ingredients in the investigational drug or murine protein-containing products
- •14.Patients with serious comorbidity (e.g., hepatic, renal, cardiac, lung, hematologic, or brain disease)
- •15.Female patients who are pregnant, lactating, or potentially pregnant, or patients who are not willing to use contraceptive measures during the study period
- •16.Patients who are judged to be unsuitable by the investigator or a sub-investigator
研究者
相似试验
已完成
2 期
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
已完成
不适用
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
已完成
不适用
The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathyJPRN-UMIN000027050Hyogo College of Medicine5
进行中（未招募）
不适用
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPMedDRA version: 9.1Level: LLTClassification code 10037562THROMBOTIC THROMBOCYTOPENIC PURPURAEUCTR2010-018794-38-ITFONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
已完成
不适用
Rituximab therapy for refractory pemphigusJPRN-jRCTs031180405Funakoshi Takeru20